TP53 and cancer: KRAS and TP53 mutation frequencies remained significantly lower in incident compared to prevalent cancers (1/19 vs. 5/9, p = 0.0066 and 0/14 vs. 4/9 [38], p = 0.0142, respectively) also when restricting the analysis to only MLH1 carriers from both groups.